Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial - Concepedia

Concepedia

Publication | Closed Access

Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial

56

Citations

20

References

2010

Year

Henrik Schmidt, Janet Brown, Ulrik Mouritzen, Peter J. Selby, Kirsten Fode, Inge Marie Svane, Graham P. Cook, David Hal Mollerup, Poul Geertsen

Clinical Cancer Research

Abstract

Outpatient treatment with s.c. administered IL-21 was tolerated and had dose-dependent pharmacodynamics. rIL-21 showed antitumor activity in patients with MM and RCC.

References

	Year	Citations

Page 1